Metraipolis › archive › dc_aa7a30ffa242
Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma — Europe PMC PMID:41521802
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41521802
- DOI
- 10.1002/cam4.71531
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T05:44:04.455Z
- SHA-256 of the archived text
644eb3f606787ef690ebb4330d80b9c6e25a16f5599caa108b0ed767331abba6- Stable URL of this page
https://metraipolis.com/documento/dc_aa7a30ffa242
How to cite
Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma — Europe PMC PMID:41521802 — Europe PMC (en), https://europepmc.org/article/MED/41521802 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_aa7a30ffa242 (Metraipolis archive dc_aa7a30ffa242, sha256 644eb3f606787ef690ebb4330d80b9c6e25a16f5599caa108b0ed767331abba6)
BibTeX
@misc{dcaa7a30ffa242,
title = {Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma — Europe PMC PMID:41521802},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41521802},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_aa7a30ffa242; sha256 644eb3f606787ef690ebb4330d80b9c6e25a16f5599caa108b0ed767331abba6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41521802. Agents can read the archived copy with the MCP tool read_document.